Norwood begins phase 2 trial of Lupron Depot with melanoma vaccine

New York, Nov. 17 - Norwood Abbey Ltd. said its Norwood Immunology Ltd. subsidiary has begun the phase 2 clinical trial of its Lupron Depot injection with a melanoma cancer vaccine.

The study is being carried out to determine if use of Norwood's technology as an adjuvant therapy provokes an enhanced immune response to an investigational melanoma cancer vaccine.

Patrick Hwu, professor and chair of Melanoma Medical Oncology at the University of Texas M.D. Anderson Cancer Center in Houston, is supervising the trial. Norwood Immunology is funding the work with support from its U.S. licensing partner, TAP Pharmaceutical Products Inc., and grants.

Norwood Immunology has licensed its immunology intellectual property to TAP Pharmaceutical Products for commercialization in the United States, using TAP's GnRH analogue, Lupron Depot (leuprolide acetate for depot suspension). The companies are exploring the use of Lupron Depot in regenerating the thymus gland and in turn "re-booting" the body's immune system, enabling patients to better recover from lifethreatening diseases.

Norwood is a Melbourne, Australia, medical technology company. TAP, based in Lake Forest, Ill., is a joint venture between Abbott Laboratories and Takeda Pharmaceutical Co. Ltd.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.